KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Operating Leases (2019 - 2025)

Historic Operating Leases for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $51.3 million.

  • GoodRx Holdings' Operating Leases rose 750.61% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year increase of 750.61%. This contributed to the annual value of $46.0 million for FY2024, which is 488.19% down from last year.
  • Latest data reveals that GoodRx Holdings reported Operating Leases of $51.3 million as of Q3 2025, which was up 750.61% from $52.7 million recorded in Q2 2025.
  • GoodRx Holdings' Operating Leases' 5-year high stood at $56.3 million during Q1 2023, with a 5-year trough of $32.0 million in Q3 2021.
  • Its 5-year average for Operating Leases is $44.2 million, with a median of $47.7 million in 2024.
  • In the last 5 years, GoodRx Holdings' Operating Leases soared by 7309.92% in 2023 and then plummeted by 1274.86% in 2025.
  • Quarter analysis of 5 years shows GoodRx Holdings' Operating Leases stood at $33.6 million in 2021, then soared by 61.14% to $54.1 million in 2022, then dropped by 10.58% to $48.4 million in 2023, then decreased by 4.88% to $46.0 million in 2024, then rose by 11.34% to $51.3 million in 2025.
  • Its Operating Leases was $51.3 million in Q3 2025, compared to $52.7 million in Q2 2025 and $44.8 million in Q1 2025.